Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study

Metastatic Breast ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Previously Treated ◽

The Impact ◽

Pyrotinib or Lapatinib Combined with Capecitabine in Women with HER2-Positive Metastatic Breast Cancer Previously Treated with Taxanes, Anthracyclines, And/Or Trastuzumab: An Open-Label, Randomised, Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3288216 ◽

2018 ◽

Author(s):

Fei Ma ◽

Quchang Ouyang ◽

Binghe Xu ◽

Wei Li ◽

Zefei Jiang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Study ◽

Previously Treated

Abstract OT2-01-08: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), HER2- metastatic breast cancer

10.1158/1538-7445.sabcs16-ot2-01-08 ◽

2017 ◽

Author(s):

V Diéras ◽

E Hamilton ◽

EL Johnston ◽

T Forrester ◽

M Martín

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽

Previously Treated

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3365080 ◽

2019 ◽

Author(s):

Kenji Tamura ◽

Chiyo K. Imamura ◽

Toshimi Takano ◽

Shigehira Saji ◽

Takeharu Yamanaka ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase

Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor‐positive, HER2 ‐negative metastatic breast cancer

International Journal of Cancer ◽

10.1002/ijc.33613 ◽

2021 ◽

Author(s):

Hyehyun Jeong ◽

Jae Ho Jeong ◽

Jeong Eun Kim ◽

Jin‐Hee Ahn ◽

Kyung Hae Jung ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Protective Effects ◽

Phase 2 ◽

Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.519 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 519-519 ◽

Cited By ~ 3

Author(s):

Joyce O'Shaughnessy ◽

Mario Campone ◽

Etienne Brain ◽

Patrick Neven ◽

Daniel F. Hayes ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast ◽

Abiraterone Acetate ◽

Phase 2 ◽

Phase 2 Study ◽

Estrogen Receptor Positive ◽

Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer

Acta Oncologica ◽

10.1080/0284186x.2020.1851045 ◽

2020 ◽

pp. 1-8

Author(s):

Anne Sofie Brems-Eskildsen ◽

Søren Linnet ◽

Hella Danø ◽

Adam Luczak ◽

Peter Michael Vestlev ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Oral Capecitabine ◽

Phase 2 Study ◽

Metronomic Treatment ◽

Faculty of 1000 evaluation for Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718133753.793486397 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽

Previously Treated ◽

Etirinotecan Pegol

Abstract OT3-1-10: HERmione: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with physician's choice of chemotherapy plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer, previously treated with pe

10.1158/1538-7445.sabcs14-ot3-1-10 ◽

2015 ◽

Author(s):

Kathy Miller ◽

Javier Cortes ◽

Sara A Hurvitz ◽

Ian E Krop ◽

Debu Tripathy ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Previously Treated ◽

Open Label Trial

Abstract S2-05: Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) withBRCA1orBRCA2mutations and metastatic breast cancer: A randomized, phase 2 study

10.1158/1538-7445.sabcs16-s2-05 ◽

2017 ◽

Cited By ~ 6

Author(s):

HS Han ◽

V Diéras ◽

ME Robson ◽

M Palácová ◽

PK Marcom ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽

Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)

10.1158/1538-7445.sabcs19-gs1-03 ◽

2020 ◽

Cited By ~ 1

Author(s):

Ian E Krop ◽

Cristina Saura ◽

Toshinari Yamashita ◽

Yeon Hee Park ◽

Sung-Bae Kim ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Previously Treated